COVID-19: Diagnosis and Management-Part II

COVID-19: Diagnosis and Management-Part II

The coronavirus disease 2019 (COVID-19) outbreak has spread throughout the globe and much time has passed since it was declared as a pandemic by the World Health Organization (WHO). COVID-19: ...
[view complete introduction]

US $
15

*(Excluding Mailing and Handling)



The Future of COVID-19 Treatment

Pp. 169-200 (32)

DOI: 10.2174/9781681088051121010009

Author(s): Sahil Arora, Manvendra Kumar, Gaurav Joshi*, Raj Kumar*

Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) or coronavirus disease or COVID-19 is a disease that has led to colossal mortality worldwide. The fast spread of this disease has caused havoc and panic among individuals, which has further worsened with the unavailability of vaccines or some proven drug regime. To date, only 12 new antiviral drugs have been approved by the FDA (8 against hepatitis C virus (2 in combinations for HIV). Thus, it becomes of utmost importance to identify drugs for new and re-emerging viruses, including the coronavirus. Considering the quest, we have put forth this book chapter to update readers about current repurposed and experimental drugs for this novel coronavirus. The viral lifecycle assisted in providing vital potential targets for drug therapy. The present chapter also deals with the existing mechanism of action of the drugs, their category, and clinical data reported.

Keywords:

ACE2 inhibitors, Antiarrhythmic, Antibacterial, Anticancer, Anticoagulants, Antidiabetic, Antifungal, Anti-inflammatory, Antimalarial, Antioxidant, Antiparasitic, Antiprotozoal, Antiviral, Chelating agents, COVID- 19, Drug repurposing, Natural products, Psychotropics, RAAS-ACE-ARBs inhibitors, SARS-CoV-2.